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Abstract: Over the past six decades, behavior therapy has been a major contributor to the development
of evidence-based psychotherapy treatments. However, a long-standing concern with behavior therapy
among many nonbehavioral clinicians has been the potential risk for symptom substitution. Few studies
have been conducted to evaluate symptom substitution in response to behavioral treatments, largely
due to measurement and definitional challenges associated with treated psychiatric symptoms. Given
the overt motor and vocal tics associated with Tourette’s disorder, it presents an excellent opportunity
to empirically evaluate the potential risk for symptom substitution associated with behavior therapy.
The present study examined the possible presence of symptom substitution using four methods: (a) the
onset of new tic symptoms, (b) the occurrence of adverse events, (c) change in tic medications, and (d)
worsening of co-occurring psychiatric symptoms. Two hundred twenty-eight participants with
Tourette’s disorder or persistent motor or vocal tic disorders were randomly assigned to receive
behavioral therapy or supportive therapy for tics. Both therapies consisted of eight sessions over
10 weeks. Results indicated that participants treated with behavior therapy were not more likely to
have an onset of new tic symptoms, experience adverse events, increase tic medications, or have an
exacerbation in co-occurring psychiatric symptoms relative to participants treated with supportive
therapy. Further analysis suggested that the emergence of new tics was attributed with the normal
waxing and waning nature of Tourette’s disorder. Findings provide empirical support to counter the
long-standing concern of symptom substitution in response to behavior therapy for individuals with
Tourette's disorder.
Keywords: Tourette’s disorder; chronic tic disorder; behavior therapy; symptom substitution;
comprehensive behavioral intervention for tics

Over the past six decades, behavior therapy has been a major contributor to the
development of evidence-based psychotherapy treatments (Antony & Roemer, 2011).
However, since the earliest emergence of behavior therapy, a long-standing concern among
many psychodynamic and other nonbehavioral psychotherapists has been the potential
risk for symptom substitution associated with behavior therapy (Kazdin, 1982; Nurnberger
& Hingtgen, 1973; Tryon, 2008). This concern about symptom substitution stems from the
belief that behavior therapy is a superficial treatment that does not target the underlying
causes of psychopathology such as unconscious internal conflicts (Scahill et al., 2013). As a
result, many nonbehavioral clinicians believe that focusing on overt, observable, or
measureable behaviors—rather than the “underlying cause”—is not therapeutic and might
even cause harm if the substituted symptom is worse than the targeted one (Kazdin, 1982).
For instance, if behavior therapy was used to successfully treat one symptom of a particular
disorder, there might be an increase in other symptoms of that disorder or a worsening of a
comorbid symptom or condition.
One factor that has contributed to the continued belief in symptom substitution is
that few studies have attempted to systematically evaluate its presence in response to
behavioral interventions. This is largely attributed to the measurement and definitional
challenges that complicate the investigation of symptom substitution (Kazdin, 1982; Tryon,
2008). First, symptoms that emerge or are “substituted” need to be differentiated from the
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targeted disorder prior to the initiation of behavior therapy. As many psychiatric problems
include multiple distinct psychiatric symptoms, the clear identification of symptoms that
are present at the onset of treatment is critical to clarifying which symptoms could be
considered “new” or “substituted.” Second, a temporal relationship between the original
and substituted symptoms must be demonstrated with the new symptoms appearing
within a specific window of time. While some suggest that the primary focus should be the
time in which the patient is receiving behavior therapy (Tryon, 2008), monitoring patients
during a follow-up period after treatment can prove important as well (Kazdin, 1982).
Finally, substituted symptoms have to be associated with the behavioral intervention
beyond that of normal fluctuations of symptoms. While the internal nature of many
psychiatric symptoms complicates these measurement and definitional challenges,
psychiatric symptoms with overt behaviors present an ideal opportunity to empirically
evaluate the potential risk of symptom substitution in response to behavior therapy. For
instance, a recent randomized controlled trial (RCT) that compared psychoanalytic
psychotherapy with cognitive-behavioral therapy (CBT) for bulimia nervosa found that
CBT outperformed the psychoanalytic condition at the 2-year assessment point, with no
evidence of symptom substitution (Hollon & Wilson, 2014; Poulsen et al., 2014). The overt
nature of motor and vocal tic symptoms associated with Tourette’s disorder (TD) presents
another opportunity to empirically assess the potential presence of symptom substitution
in response to behavior therapy. Specifically, the natural occurrence of TD involves a
waxing and waning of tics (Lin et al., 2002), with the onset of new tics not being
uncommon. Therefore, the onset of new tic symptoms or worsening of tic severity that
might be perceived as “evidence” of symptom substitution may result from the natural
waxing and waning nature of tics.

Tics are sudden motor movements or vocalizations that begin in childhood and may
persist into adulthood (Leckman, 2002). A persistent motor or vocal tic disorder (PTD; also
known as chronic tic disorder) is defined by the presence of a single tic or multiple motor
or vocal tics that persist for more than a year, with the diagnosis of Tourette’s disorder
(also known as Tourette syndrome) requiring both multiple motor tics and at least one
vocal tic (not necessarily concurrently) that last more than a year (American Psychiatric
Association, 2013). The prevalence of TD ranges from 0.4 to 1.6% (Knight et al., 2012;
Scahill, Specht, & Page, 2014). Common tics in children and adults with TD/PTD include
eye blinking, head jerking, mouth movements, and simple vocalizations (McGuire et al.,
2013). In community and clinical samples, TD/PTDs are associated with a wide range of
behavioral and emotional difficulties (Conelea et al., 2011, 2013; Specht et al., 2011; Storch
et al., 2007; Sukhodolsky et al., 2003). Thus, efficient and effective treatments are needed
for individuals with TD/PTD.
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Pharmacological and behavioral interventions have demonstrated efficacy in the
management of TD/PTDs. Although significantly reducing tic severity (Singer, 2011),
antipsychotics, atypical antipsychotics, and antihypertensives rarely eliminate tics and
frequently produce unwanted side effects including sedation, weight gain, cognitive dulling,
and other adverse effects that limit tolerability and medication adherence (Scahill et al.,
2006). Meanwhile, behavior interventions have also demonstrated success in reducing tic
severity (Peterson, 2007). These behavior therapy interventions include habit reversal
training (HRT; Azrin & Peterson, 1988, 1990; Peterson & Azrin, 1992; Wilhelm et al., 2003)
and the comprehensive behavioral intervention for tics (CBIT; Piacentini et al., 2010;
Wilhelm et al., 2012; Woods et al., 2008). Notably, HRT serves as the principle therapeutic
ingredient in CBIT, which incorporates functional assessment and function-based
intervention procedures to mitigate influences of daily life that worsen tics. Despite the
demonstrated efficacy of behavior therapy (McGuire et al., 2014), it is not widely used, in
part due to misconceptions about the nature and treatment of tics that continue to persist
among practitioners (Marcks, Woods, Teng, & Twohig, 2004; Woods, Conelea, & Walther,
2007). A common concern is that symptom substitution will occur with behavior therapy
for tics, meaning that treatment of a given tic could result in the onset of new tic symptoms,
an increase in severity of other tics, or the worsening of co-occurring psychiatric
symptoms. For instance, if a head jerk tic improved or remitted with behavior therapy, the
concern might be that the patient would develop a new “substituted” tic (e.g., arm twitch)
in its place, and/or the patient would experience worsening of co-occurring
psychopathology.

Although symptom substitution with behavior therapy has been a long-standing
concern among nonbehavioral psychotherapists (Kazdin, 1982), there are only a few
clinical anecdotes and uncontrolled case studies that provide support for this concept in
TD/PTD (Burd & Kerbeshian, 1987, 1988), with similarly minimal empirical evaluation to
refute this claim. Woods, Twohig, Flessner, and Roloff (2003) provided preliminary data to
challenge the notion of symptom substitution associated with behavior therapy. Woods and
colleagues (2003) treated five children with multiple motor and vocal tics using HRT, but
only targeted vocal tics. While vocal tics were reduced in four of the five children, the
untreated motor tics did not increase and new tic symptoms were not reported to develop.
Additionally, there was an 83% reduction in the targeted vocal tics and a 26% reduction in
the untreated motor tics. These initial results suggest that behavior therapy may actually
generalize to improvements in other nontreated symptoms, with no evidence of symptom
substitution. Although noteworthy, this preliminary study was limited in sample size and
scope of co-occurring psychiatric symptoms.
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The present study empirically examined possible symptom substitution associated
with behavior therapy using data combined from two previously published RCTs of
children (Piacentini et al., 2010) and adults (Wilhelm et al., 2012). While the primary
outcomes from these two RCTs demonstrated that participants receiving behavior therapy
exhibited significant reductions in tic severity and had a greater treatment response than
participants receiving supportive therapy, these two trials did not examine for the
presence of symptom substitution. This secondary data analysis included 228 participants
with TD/PTD from the previously published RCTs who had been randomly assigned to
receive either behavior therapy or supportive therapy for the treatment of motor and vocal
tics. Based on the measurement and definitional challenges noted above, the presence of
symptom substitution was evaluated using four methods: (a) the emergence of new tic
symptoms during treatment, (b) the occurrence of adverse events during treatment, (c)
change in tic medications during treatment, and (d) worsening co-occurring symptoms
after treatment. Furthermore, we explored factors that were associated with the onset of
new tic symptoms across treatment conditions. Based on the findings of Woods and
colleagues (2003), we hypothesized that behavior therapy would not be associated with
the onset of new tics, the occurrence of adverse events, increase in tic medication, or
worsening of co-occurring psychiatric symptoms relative to the supportive therapy
condition.

Materials and Methods
Participants

The participants (N = 228) included 134 children and 94 adults with TD/PTD who
were treated in two parallel RCTs examining the efficacy of a behavior therapy compared
with a psychoeducation and supportive therapy (Piacentini et al., 2010; Wilhelm et al.,
2012). An identical randomized two-group design was used for both the child and adult
RCTs, and participants received eight sessions of behavior therapy or supportive therapy
over a 10-week period. Primary assessments were conducted at the baseline, 5-week
(midtreatment), and 10-week (posttreatment) assessment points, with a 6-month followup assessment completed by treatment responders. The participant demographic and
clinical characteristics are presented in Table 1. With the noted exception of age, the two
studies employed similar inclusion/exclusion criteria. Inclusion criteria included the
following: (a) a TD/PTD of moderate or greater severity, (b) English fluency, (c) an
estimated IQ > 80, and (d) unmedicated or at least 6 weeks on stable dose of tic
medications with no planned changes. Exclusion criteria included the following: (a) an
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unstable medical condition; (b) current diagnosis of substance abuse/dependence; (c)
lifetime diagnosis of pervasive developmental disorder, mania, or psychosis; and (d) four
or more previous sessions of behavior therapy.
Table 1. Demographic and Clinical Characteristics of the Sample
Characteristic
Male
Adult
Co-occurring OCD
Co-occurring ADHD
Taking tic medication

Total sample (N = 228)
N (%)
161 (71%)
94 (41%)
43 (19%)
61 (27%)
72 (32%)

CBIT (n = 116)
n (%)
78 (67%)
50 (43%)
20 (17%)
34 (29%)
38 (33%)

PST (n = 112)
n (%)
83 (74%)
44 (39%)
23 (21%)
27 (24%)
34 (30%)

χ2
1.29
0.34
0.40
0.79
0.15

Mean (SD)
Range Mean (SD)
Mean (SD)
t
Age
21.57 (14.19) 9–70
22.05 (14.18) 21.06 (14.25) 0.53
Baseline YGTSS total tic score
23.90 (6.46)
10–45 24.41 (6.48)
23.38 (6.43) 1.20
Baseline YGTSS impairment score
23.91 (7.88)
5–50
24.09 (8.20)
23.72 (7.56) 0.35
Number of baseline tics on HM/VTS 6.25 (2.05)
1–10
6.33 (2.01)
6.16 (2.10)
0.62
Note. CBIT = comprehensive behavioral intervention for tics; PST = psychoeducational and supportive
therapy; OCD = obsessive–compulsive disorder; ADHD = attention deficit/hyperactivity disorder;
YGTSS = Yale Global Tic Severity Scale; HM/VTS = Hopkins Motor/Vocal Tic Scale.
*p < .05.

Measures

Diagnostic Interviews

Age-appropriate structured diagnostic interviews were used to assess tic and
relevant co-occurring diagnoses at baseline. Given their common co-occurrence in the
presentation of TD/PTD, relevant co-occurring diagnoses are obsessive–compulsive
disorder (OCD) and attention deficit/hyperactivity disorder (ADHD). Child study
participants were administered the child version of the Anxiety Disorders Interview
Schedule (ADIS) for DSM-IV-TR (Silverman & Albano, 1996; Silverman, Saavedra, & Pina,
2001; Wood, Piacentini, Bergman, McCracken, & Barrios, 2002). Adult participants were
administered the Structured Clinical Interview for DSM-IV (SCID; First, Spitzer, Gibbon, &
Williams, 2002).
New Bothersome Tic Symptoms

Participants identified up to five motor and five phonic tics deemed most
bothersome at the baseline assessment using a modified version of the Hopkins
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Motor/Vocal Tic Scale (HM/VTS; Walkup, Rosenberg, Brown, & Singer, 1992), which has
demonstrated strong reliability and validity with other measures of tic severity. These tics
were then rated on a 5-point scale that ranged from 0 (none) to 4 (severe) by an
independent evaluator masked to treatment condition.
Tic Severity

Tic severity over the previous week was assessed using the Yale Global Tic Severity
Scale (YGTSS; Leckman, Riddle, Hardin, & Ort, 1989; Storch et al., 2005), a clinician-rated
scale with demonstrated excellent reliability and validity. The YGTSS includes a symptom
checklist of 40 commonly reported motor and vocal tics and yields four tic severity scores:
total motor and total phonic score (range 0–25), total tic score (range 0–50), and
impairment score (range 0–50). Tic severity on the YGTSS total tic score corresponds with
the following definitions: minimal tics (1–9), mild tics (10–19), and moderate or greater
tics (> 20; Bloch & Leckman, 2009).
Global Improvement

Primary treatment outcome regarding tic reductions was assessed using the Clinical
Global Impression–Improvement Scale (CGI-I; Guy, 1976), a single-item clinician rating of
overall change in clinical presentation from baseline. CGI-I scores range from 1 (very much
improved) to 7 (very much worse). Ratings of very much improved and much improved
were used to classify positive treatment response.
Adverse Event Monitoring Form

Adverse events were assessed prior to each therapy visit using a structured form
with scripted questions that reviewed a wide array of current health concerns and
medication use/changes (Piacentini et al., 2010; Wilhelm et al., 2012).
Co-occurring Symptoms

The most common co-occurring symptoms associated with TD/PTD were measured
in both children and adult RCTs at baseline, posttreatment, and the 6-month follow-up
assessment. This included ADHD, OCD, depression, and anxiety in both samples and
oppositional defiant disorder behavior (ODD) in the child sample. As a result of ongoing
data analyses, secondary outcomes on the adult CBIT study were unavailable, and only data
on the child CBIT study are presented below. In the child RCT, ADHD was measured using
the 18-item ADHD Rating Scale (ADHD-RS; DuPaul, Power, Anastopoulos, & Reid, 1998).
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OCD symptoms were assessed using the 10-item Children’s Yale–Brown Obsessive
Compulsive Scale (CY-BOCS; Scahill et al., 1997). ODD behavior was measured with the
eight-item Disruptive Behavior Rating Scale (DBRS; Barkley, 1997). Depression was
assessed with the 27-item Children’s Depression Inventory (CDI; Kovacs, 1992). Anxiety
was measured with the Screen for Child Anxiety Related Emotional Disorders (SCARED;
Birmaher et al., 1997).

Treatment

The behavior therapy treatment was the CBIT (Woods et al., 2008), which is an
enhanced version of the behavior therapy treatment called habit reversal (Azrin &
Peterson, 1988, 1990; Peterson & Azrin, 1992; Wilhelm et al., 2003). CBIT includes six
primary components: awareness training, functional assessment and intervention,
contingency management, relaxation training, competing response training, and
generalization training (Woods et al., 2008). The primary component that targets tic
reduction is the competing response procedure. Competing responses are behaviors that
are incompatible with the tics, such as the isometric tensing of muscles opposite to the tic
movements. Competing responses are designed to be able to be sustained for a brief period
of time (e.g., at least 1 minute), to be inconspicuous, and to be compatible with ongoing
activities. A tic hierarchy is developed, and then competing responses are implemented
sequentially across treatment sessions starting with the most bothersome tic.

The psychoeducation and supportive therapy served as the comparison condition,
and was designed to be similar to the standard supportive counseling that might be
received in a community mental health clinic and to parallel the recommended adjunctive
components of psychopharmacological treatment for individuals with TD/PTD (Goetz &
Horn, 2005). It did not include any of the elements of behavior therapy, but offered
educational information and support to help patients learn to better manage their tics. It
provided disorder-specific information about the course, genetics, underlying neurobiology
of TD/PTD, and the rationale for current treatments. Participants were permitted to
discuss tics and related issues as part of supportive therapy, but therapists were instructed
not to provide advice or specific interventions for tic management (Piacentini et al., 2010;
Wilhelm et al., 2012).

Procedures

Procedures were reviewed and approved by the institutional review boards at each
performance site, and all participants provided written informed consent (assent and
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parental permission for minors). All procedures were performed in compliance with
relevant laws and institutional guidelines in accordance with the ethical standards of the
responsible committee on human experimentation (institutional and national) and with
the Helsinki Declaration of 1975, as revised in 2000. Participants were recruited from six
sites: Johns Hopkins School of Medicine; University of California, Los Angeles; University of
Wisconsin–Milwaukee; Massachusetts General Hospital/Harvard Medical School;
University of Texas Health Science Center at San Antonio; and Yale University. After
consent and assent were obtained, participants completed a baseline assessment that
included a structured diagnostic interview (ADIS or SCID), clinician-administered tic
ratings (YGTSS, HM/VTS), and ratings of co-occurring psychopathology (ADHD-RS, CYBOCS, DBRS, CDI, SCARED). Clinical assessments were completed by an independent
evaluator with a master’s degree or higher in a mental health field and trained to reliability
on the clinician-administered measures and received ongoing supervision (Piacentini et al.,
2010; Wilhelm et al., 2012). Afterward, participants were randomly assigned to receive
eight sessions of behavior therapy or supportive therapy over 10 weeks. Participants were
reassessed by the independent evaluator who was blind to treatment condition at
midtreatment (Week 5) and posttreatment (Week 10) on measures of tic symptoms
(HM/VTS), tic severity (YGTSS), and treatment response (CGI-I). The independent
evaluator specifically inquired about new bothersome tics that emerged after baseline at
each subsequent assessment. If new bothersome tics were reported, they were
documented and assessed for severity at the midtreatment and posttreatment
assessments. Additional methodological details can be found in the previously published
RCTs (Piacentini et al., 2010; Wilhelm et al., 2012).

Analytic Plan

Four procedures were used to examine possible symptom substitution. First, the
onset of new tic symptoms was examined in response to the behavior therapy that
specifically targeted the reduction of individual tics. The presence of symptom substitution
would be evident if new tics were more likely to occur in the behavior therapy condition as
compared with the supportive therapy condition. Second, the occurrence of adverse events
was evaluated for both the behavior therapy and supportive therapy conditions. Symptom
substitution would be observed if adverse events were more likely in the behavior therapy
condition compared with supportive therapy. Third, changes in tic medications that
occurred after the start of treatment were examined. Given that an increase in tic
medication might serve as a proxy for worsening tic symptoms, symptom substitution
would be observed if the behavior therapy condition had a greater frequency of tic
medication changes relative to supportive therapy. Finally, worsening of nontargeted coBehavior Therapy, Vol. 47, No. 1 (January 2016): pg. 29-41. DOI. This article is © Elsevier and permission has been granted for this version to
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occurring psychiatric symptoms was analyzed in the child RCT (Piacentini et al., 2010;
Woods et al., 2011). In this case, symptom substitution would be observed if participants in
the behavior therapy condition experienced worsening of co-occurring psychiatric
symptoms relative to the supportive therapy condition.
Onset of New Tic Symptoms

The first approach analyzed symptom substitution by examining the onset of new
tic symptoms in response to either behavior therapy or improvement in individual tic
symptoms targeted with behavior therapy. For this analysis, the HM/VTS ratings were
reviewed and entered into a database. The YGTSS symptom checklist was then reviewed to
determine and confirm the presence of new tics identified at midtreatment and
posttreatment assessments. If the identified tic had been reported at a prior assessment on
the YGTSS symptom checklist, it was assumed that the tic had increased in
bothersomeness, but it was not classified as a new tic. If the tic was not endorsed
previously on the YGTSS symptom checklist and was reported as a new tic on the HM/VTS,
the tic was classified as a new tic. Similarly, the YGTSS symptom checklist was reviewed to
determine the remission of bothersome tics identified at baseline. A tic was considered to
be remitted if it had either a HM/VTS score of 0 or was no longer endorsed on the HM/VTS
and the YGTSS symptom checklist. Of the original 248 participants, 20 had HM/VTS ratings
that were considered to be unusable (e.g., illegible, inconsistent, or missing) and were
excluded from analysis (8 CBIT, 12 PST). The remaining 228 participants were included in
the analyses; 207 had complete data at all three assessments. There was no significant
difference between the two treatment groups in terms of participants with incomplete data
on the HM/VTS at all three assessments (7 CBIT, 14 PST, χ2 = 2.85, p = .09). Chi-square and
independent sample t tests compared baseline characteristics between treatment groups.
Fisher’s exact tests and independent sample t tests assessed the relationship between
treatment conditions related to the onset of any new bothersome tics on the HM/VTS. For
those receiving behavior therapy, Fisher’s exact test and Mann–Whitney procedures with
exact significance test examined the relationship among the onset of any new bothersome
tics, categorical reductions in tic severity (a reduction of 1 point or more for any tic on the
HM/VTS), and tic remission (a zero severity rating for any tic on the HM/VTS) for any
participants whose bothersome tics served as a treatment target. Across all participants,
Fisher’s exact tests and Mann–Whitney procedures with exact significance tests explored
the relationship between the number of new bothersome tics and reductions in tic severity,
tic remission, and treatment response. Given that this was the first large-scale systematic
evaluation of symptom substitution in TD, all alternative hypotheses were two-sided, and
statistical significance was set at the p < .05 level.
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Occurrence of Adverse Events

The second approach to evaluating symptom substitution was to examine adverse
events that may have occurred as a result of behavior therapy. The monitoring of adverse
events was completed using methods similar to those used in biomedical clinical trials
(Peterson, Roache, Raj, & Young-McCaughan, for the STRONG STAR Consortium, 2013). At
the start of every therapy session, therapists asked participants about possible adverse
events (i.e., recent health complaints, behavioral changes, visits for medical/mental health
care, changes in medications, and hospitalizations). Participants were also offered the
opportunity to spontaneously report any other problem. Positive responses were
documented regardless of whether they were thought to be related to the therapy. For each
possible adverse event reported, additional details were gathered about the onset, severity,
and outcome of the event, and measures taken to address it. An increase in tics was
considered an adverse event when a participant or parent reported the worsening of a tic
at the start of a treatment session when adverse events were assessed. Fisher’s exact test
compared the incidence of worsening tic symptoms between treatment conditions for each
RCT.
Change in Tic Medications

The third approach to evaluating symptom substitution was to examine any change
in tic medications that may have occurred as a result of the behavior therapy. Participants
who were receiving psychotropic medications for tics or co-occurring psychiatric disorders
were eligible to participate in both the child and adult RCTs if the dose was stable for
6 weeks and there were no planned changes during study participation. If a participant’s tic
symptoms drastically worsened, the participant’s tic medication would likely have been
changed in response. Fisher’s exact test compared the incidence of tic medication changes
between treatment conditions for each RCT.
Worsening of Co-Occurring Psychiatric Symptoms

The final approach to evaluating symptom substitution was to examine any changes
in co-occurring psychiatric symptoms that may have occurred as a result of the treatment
of the primary tic symptom. Changes in co-occurring psychiatric outcomes were measured
for ADHD, OCD, ODD, depression, and anxiety. A complete description of the measures and
statistical analyses are included in the original secondary outcomes manuscript for the
child RCT (Woods et al., 2011). Given that similar analyses have not been completed for the
adult RCT, evaluation of changes in co-occurring symptoms was limited to the child RCT.
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Results

Participants included 228 children (n = 134) and adults (n = 94) with a primary
diagnosis of TD/PTD. A total of 116 (51%) received behavior therapy, and the remaining
participants (n = 112, 49%) received supportive therapy. Detailed participant
characteristics are found in Table 1. There were no significant differences at baseline
between treatment groups on demographic characteristics, tic severity, or the number of
bothersome tics nominated at baseline. The primary outcomes regarding tic reductions in
the original RCTs indicated that participants treated with CBIT were significantly more
likely to be classified as treatment responders on the CGI-I (child = 53%, adult = 38%,
combined sample = 45%) as compared with those treated with the supportive therapy
(child = 19%, adult = 6%, combined sample = 13%; Piacentini et al., 2010; Wilhelm et al.,
2012).

Onset of New Tics in Relation to Treatment Condition

Across both treatment conditions, participants exhibited an average of 1.25 new
bothersome tics (± 1.53 new tics) over the 10-week trial as measured by the HM/VTS.
Fisher’s exact test identified that the onset of a new tic during treatment did not differ
between behavior therapy and supportive therapy (see Table 2). Furthermore, an
independent sample t test found no difference in the number of new tics that developed
between behavior therapy and supportive therapy conditions (see Table 2). For a more
detailed analysis, the relationship between specific outcomes for tics targeted by behavior
therapy and new tic development was examined on the HM/VTS. Fisher’s exact test
revealed that the reduction or remission of any targeted tics was not associated with the
onset of a new tic during behavior therapy (see Table 2). Furthermore, Mann–Whitney
tests identified that neither a reduction or remission of any bothersome tic on the HM/VTS
was associated with the number of new bothersome tics that developed over treatment
with CBIT (see Table 2). This analysis was not conducted for the supportive therapy
condition because it did not involve the specific targeting of individual tics as part of the
treatment.
Table 2. Onset of New Tic Symptoms in Relation to Treatment Condition
CBIT
PST
(n = 116)
(n = 112)
N (%)
N (%)
Onset of a new bothersome tic symptom
72 (62%)
62 (55%) Fisher's
exact

p = .35
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CBIT
(n = 116)
N (%)
Targeted tic reduction in treatmenta and association with 100 (90%)
any new tic onset
Targeted tic remission in treatmenta and association
60 (54%)
with any new tic onset
Targeted tic reduction in treatmenta and association with 100 (90%)
the number of new bothersome tics
Targeted tic remission in treatmenta and association
60 (54%)
with the number of new bothersome tics
Mean (SD)
Number of new bothersome tics
1.25 (1.43)

PST
(n = 112)
N (%)
N/A
Fisher's
p = .74
exact
N/A
Fisher's
p = .43
exact
N/A
z = –1.15 .25
N/A

z = –1.03 .31

Mean (SD)
1.26 (1.64) t226 = –
p = .97
0.04,
Note. CBIT = comprehensive behavioral intervention for tics; PST = psychoeducational and supportive
therapy; N/A = not applicable; SD = standard deviation.
a111 participants in CBIT condition had tics nominated on Hopkins Motor/Vocal Tic Scale that were
targeted in treatment.

Association of New Tic Onset with Severity Reductions, Remission, and Clinical
Response

Given that there was no difference in the onset of new tic symptoms between
treatment conditions, subsequent analyses explored whether the full remission of a tic or a
reduction in the severity of any tic (targeted and nontargeted) on the HM/VTS was
associated with new tic incidence across treatment conditions (N = 228). A Fisher’s exact
test identified that only the full remission of a bothersome tic (whether targeted by
treatment or not) prior to midtreatment (Week 5) was associated with the onset of a new
bothersome tic during that same 5-week interval (Fisher’s exact test, p = .04). Among the
134 participants who experienced the remission of a tic before Week 5, 68 participants
(51%) reported the onset of a new bothersome tic. Among 87 participants who did not
experience the remission of a bothersome tic over this interval, 31 (36%) participants
reported the onset of a new bothersome tic. Meanwhile, a reduction in the severity (but not
full remission) of any bothersome tic was not associated with the onset of a new
bothersome tic during the first half of treatment (Fisher’s exact test, p = .81). In addition,
Fisher’s exact tests identified that neither a decrease in severity (p = .78) nor full
remission (p = .28) of any bothersome tics during the initial 5 weeks of treatment was
associated with the onset of a new bothersome tic during the latter half of treatment.
Furthermore, a reduction in tic severity (Fisher’s exact test, p = 1.00) and full remission
(Fisher’s exact test, p = .26) of any bothersome tic during the second 5 weeks of therapy
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was not associated with the onset of a new bothersome tic during this time interval. For a
dimensional perspective, Table 3 examines the number of new bothersome tics that
developed over the 10-week trial as a function of tic severity reduction, tic remission, and
treatment response. Remission of any bothersome tic during the first or second half of
treatment was associated with an average onset of two new bothersome tics. Participants
not exhibiting tic remission at either interval had, on average, less than one new tic onset
during the 10-week trial. Participants who experienced a reduction in the severity of any
bothersome tic in the latter half of treatment had an average of 1.38 new bothersome tics
develop. Those who did not experience a reduction in the same time window developed an
average of 0.65 new bothersome tics. Treatment response on the CGI-I was not associated
with the development of an increased number of new bothersome tics.
Table 3. Categorical Predictors of New Bothersome Tics Over 10-Week Therapy Period

Categorical predictor
Yes
M ± SD
No
M ± SD
z
p
Decreased tic severity BL to W5
202 1.28 ± 1.55 20 0.95 ± 1.47 –1.24 .215
Tic remission BL to W5
134 1.52 ± 1.73 87 0.84 ± 1.11 –2.94 .003
Decreased tic severity W5 to W10
189 1.38 ± 1.59 20 0.65 ± 0.93 –2.09 .037
Tic remission W5 to W10
144 1.54 ± 1.66 63 0.79 ± 1.12 –3.44 .001
Decreased tic severity from BL to W10
213 1.30 ± 1.55 4
1.50 ± 1.73 –0.31 .756
Tic remission from BL to W10
185 1.44 ± 1.59 31 0.52 ± 0.96 –3.60 < .001
CGI-I treatment responder at W5
31 1.16 ± 1.37 196 1.28 ± 1.56 –0.15 .877
CGI-I treatment responder at W10
71 1.13 ± 1.27 144 1.37 ± 1.65 –0.53 .594
Note. BL = baseline; W5 = Week 5; W10 = Week 10; CGI-I = Clinical Global Impression–Improvement
Scale.

Occurrence of Adverse Events

In the child RCT (Piacentini et al., 2010), 200 adverse events were reported during
the 10-week trial (76 in the behavior therapy condition and 124 in the supportive therapy
condition). Adverse events were categorized into 13 different symptom clusters (e.g.,
upper respiratory infection, headache, tic worsening). There were no statistically
significant differences between conditions for 12 of the 13 symptom clusters (see
Piacentini et al., 2010, for a detailed list of all adverse events). Although falls and athletic
injuries occurred more often in the supportive therapy condition (n = 19) than in the
behavior therapy condition (n = 7, p = .02, Fisher’s exact test), there was no significant
difference in tic worsening above and beyond usual fluctuations reported between the
behavior therapy group (n = 1, 2%) relative to supportive therapy (n = 4, 6%, p = .37,
Fisher’s exact test). In the adult RCT (Wilhelm et al., 2012), 224 adverse events were
reported during the 10-week trial (92 in the behavior therapy condition and 102 in the
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supportive therapy condition). Adverse events that occurred with more than 5% of study
participants in each group were then categorized into 12 different symptom clusters. There
were no statistically significant differences between groups for 11 of the 12 symptom
clusters (see Wilhelm et al., 2012, for a detailed list of all adverse events). Irritability
occurred more often in the supportive therapy condition (n = 6) than in the behavior
therapy condition (n = 0, p = .01, Fisher’s exact test). Similar to the child RCT, tic
worsening above and beyond usual fluctuations was reported by four participants (6%) in
the behavior therapy condition and four participants (7%) in the supportive therapy group
(p = .99, Fisher’s exact test).

Changes in Tic Medications

In the child RCT (Piacentini et al., 2010), 23 participants (38%) in the behavior
therapy group and 23 participants (35%) in the supportive therapy group were taking tic
medications at baseline. Two participants in the behavior therapy group (3%) and four
participants in the supportive therapy group (6%) reported a change in their tic
medication type or dose during acute treatment (p = .68, Fisher’s exact test). In the adult
RCT (Wilhelm et al., 2012), 17 participants (27%) in the behavior therapy group and 14
participants (24%) in the supportive therapy group were taking tic medications at the start
of the study. None of the participants in the behavior therapy group reported a change in
their tic medication type or dose during the treatment and only one participant in the
supportive therapy group reported a change in medication type or dose (p = .48, Fisher’s
exact test).

Worsening of Co-Occurring Psychiatric Symptoms

The results of the analysis of the secondary outcomes at posttreatment and 6-month
follow-up assessments indicated that there were no statistically significant differences
between those participants treated with behavior therapy and supportive therapy in terms
of changes in any of the co-occurring symptoms (Woods et al., 2011). At the posttreatment
assessment point, the measures of ADHD, OCD, ODD, depression, and anxiety were all
improved for both behavior therapy and supportive therapy, but there were no statistically
significant differences between treatment conditions (Woods et al., 2011). At the 6-month
follow-up assessment, responders to behavior therapy exhibited decreased anxiety,
disruptive behavior, family strain, and improved social functioning (Woods et al., 2011).
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Discussion

This study examined the presence of symptom substitution in response to behavior
therapy using the combined data from two published RCTs on the treatment of TD/PTD
(Piacentini et al., 2010; Wilhelm et al., 2012). Possible symptom substitution was examined
using the following four methods: (a) the onset of new tic symptoms, (b) the occurrence of
adverse events, (c) changes in tic medications, and (d) worsening of co-occurring
psychiatric symptoms. First, the results suggested that the onset of new tic symptoms
during treatment did not significantly differ between behavior therapy and supportive
therapy conditions. These findings are noteworthy considering that the participants
receiving behavior therapy were more likely to be considered treatment responders on the
CGI-I (45% response rate) as compared with supportive therapy (13% response rate;
Piacentini et al., 2010; Wilhelm et al., 2012). Second, the examination of adverse events
suggested that participants receiving behavior therapy were not more likely to experience
a worsening of tic symptoms or other adverse events relative to supportive therapy.
Conversely, there were more adverse events related to supportive therapy compared with
behavior therapy, but in most cases the differences were not statistically significant. Third,
the examination of tic medications found that there was no difference in tic medication
changes between treatment conditions. Finally, the examination of secondary psychiatric
outcomes in the child RCT highlighted overall improvements in nontargeted co-occurring
symptoms related to both treatments at both posttreatment and follow-up assessments
(Woods et al., 2011). This finding is consistent with the general findings from most
behavior therapy treatments, namely that improvements in secondary symptoms are often
found to correlate with improvements in the primary targeted symptoms (Antony &
Roemer, 2011). Taken together, these findings highlight that symptom substitution was not
more likely to occur to participants receiving behavior therapy compared with supportive
therapy across these four methods.

Given that the onset of new tic symptoms was not associated with treatment
condition, we explored other factors to understand the origins of new bothersome tics in
treatment. Across both treatment conditions, the onset of a new bothersome tic was
associated with the full remission of a bothersome tic within the 10-week treatment period.
Specifically, the remission of a bothersome tic within the first 5 weeks of the treatment was
associated with the onset of a new bothersome tic during this same time window across
treatment conditions. Stated differently, if a bothersome tic remitted, then a new
bothersome tic was more likely to develop during treatment. These findings suggest that
the onset of new tics is not a consequence of behavior therapy, and is most likely associated
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with the normal waxing and waning of TD/PTD as it occurred equally across treatment
conditions (Lin et al., 2002). Indeed, participants typically reported the onset of one to two
new bothersome tics over the 10-week treatment period. In regard to treatment outcome,
there was no association between treatment response on the CGI-I and either the onset of a
new bothersome tic or the number of new bothersome tics. Stated differently, if
participants responded to treatment in either group, they were at no greater risk of
developing new bothersome tics compared with participants who did not respond to
treatment. From a broad perspective, the development of occasional new tics during
therapy should be seen as part of the natural waxing and waning of tics. The changing
nature of tic symptoms may be attributed in part to premonitory urge presence, as tics
without premonitory urges were more likely to remit compared with tics with a
premonitory urge (McGuire et al., 2015). Moreover, the development of occasional new tics
was not associated with negative treatment outcomes in either treatment condition, with
no available evidence suggesting that new bothersome tics will respond less well to
treatment. Indeed, emerging research has identified specific tic characteristics and
individual tics may be better candidates for treatment behavior therapy (McGuire et al.,
2015).

To the best of our knowledge, the present study is the largest to empirically examine
possible symptom substitution associated with behavior therapy in TD/PTD. However, this
study should be interpreted within the context of its limitations. First, the analysis included
a combined data set from two previous studies of children and adults. The original studies
were conducted separately because of the differences required in the assessment and
treatment of these participant populations. Although the research design, methods, and
primary outcomes were almost identical, slight differences between the studies may have
added some unidentified or unspecified confounds. Second, no missing data imputation
strategies were used. This impacted 21 participants who had missing data on the HM/VTS
at either midtreatment or posttreatment. Although this may have influenced our ability to
identify the presence/remission of tics, most participants (91%) had complete data at all
three assessment points. Moreover, there were no significant differences in missing data
between treatment groups. Third, given the focus on concerns of symptom substitution in
response to behavior therapy, some clinical and demographic characteristics were not
examined and could possibly be associated with the development of new bothersome tics.
Finally, it could be argued that the present study is not technically a true test of symptom
substitution because that would have required the comparison of behavior therapy with
psychoanalytic treatment rather than supportive therapy.
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Conclusions

The present study evaluated a long-standing concern among many psychodynamic
and other nonbehavioral psychotherapists related to the potential risk of symptom
substitution associated with behavior therapy (Kazdin, 1982; Nurnberger & Hingtgen,
1973; Tryon, 2008). Across the few prior studies of symptom substitution, there has been
limited evidence supporting its existence among anxiety disorders, enuresis, conversion
disorder, habit conditions, and bulimia nervosa (Fuchs, 1980; Hollon & Wilson, 2014;
Nurnberger & Hingtgen, 1973; Poulsen et al., 2014; Speed, 1996; Wille, 1993; Wille &
Anveden, 1995). While there have been a few reports suggesting that what was perceived
as symptom substitution, a closer review suggests that it was more consistent with
spontaneous recovery, relapse, or an extinction burst following discontinuation of behavior
therapy (see Tryon, 2008). Although noteworthy, these prior examinations were mostly
limited by small sample sizes and the methodological challenges associated with evaluating
symptom substitution (Kazdin, 1982; Nurnberger & Hingtgen, 1973; Tryon, 2008), with
only one study using an RCT design (Hollon & Wilson, 2014; Poulsen et al., 2014).
Following design recommendations (Tryon, 2008), the present study compared two
groups of demographically matched participants who received either behavior therapy
targeted at reducing individual tics or psychoeducation and supportive therapy. In contrast
to the concerns about the potential negative effects of behavior therapy, the results
suggested that the positive benefits of behavior therapy generalized beyond the primary
targeted behavior of tic reductions and also resulted in reductions in untreated comorbid
symptoms at a 6-month follow-up assessment. Similarly, in contrast to the concerns of the
possible detrimental effects of behavior therapy, there were fewer negative side effects
with the CBIT intervention as compared with supportive therapy. While some
methodological limitations and challenges exist in the present study, the results identify no
difference in symptom substitution between behavior therapy and a nonbehavioral
treatment.
For several decades, concerns regarding symptom substitution have served as
barriers to the dissemination and implementation of behavior therapy for Tourette’s
disorder (Marcks et al., 2004; Scahill et al., 2013; Woods et al., 2007). Based on the results
of the present study, future educational efforts should attempt to correct the
misconceptions about behavior therapy among mental health clinicians, medical providers,
patients, and families (Scahill et al., 2013). Similar concerns have undoubtedly been
expressed about behavior therapy as applied to other conditions. While this study adds to
the growing evidence base against symptom substitution (Hollon & Wilson, 2014; Poulsen
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et al., 2014), additional research is needed to evaluate the potential risks and benefits of
behavior therapy for other disorders. Such efforts may help to further reduce the barriers
to care and enhance the public health impact of behavior therapy.
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